poster

Updated Cost-Effectiveness Analysis of Brexpiprazole for Adjunctive Treatment in Major Depressive Disorder in the United States

Abstract: Background: A 2017 published cost-effectiveness analysis of brexpiprazole compared to quetiapine-150 mg/day, quetiapine-300 mg/day, olanzapine/fluoxetine 50mg-12mg/day and antid...

01/19/2023

Prevalence of Pharmacogenomic Actionability in >11,000 Patients Receiving Psychiatric Care

Abstract: Introduction: Most patients with major depressive disorder (MDD) fail first-line antidepressant treatment. Pharmacogenomic (PGx) testing may improve drug selection and/or dosing...

01/19/2023

Comorbidities and Presenting Symptoms in a Real-World Population With Obstructive Sleep Apnea

Abstract: Background: Obstructive sleep apnea (OSA) is a sleep disorder that is often comorbid with psychiatric disorders. Excessive daytime sleepiness (EDS) is common in both psychiatric...

01/19/2023

Anticholinergics Should Not Be Used to Treat Tardive Dyskinesia: Insights from an Expert Panel of Psychiatry and Neurology Healthcare Professionals

Abstract: Background: Treating tardive dyskinesia (TD) with anticholinergics is a common practice, despite the lack of supportive evidence and potential to worsen TD. Methods: Eight move...

01/19/2023

Prevention in Practice: Improving Communication on the Benefits of Treatments for Schizophrenia

Abstract: Antipsychotic treatment can help improve outcomes in schizophrenia by reducing the risk of relapse and psychiatric hospitalization, and increasing rates of remission and recover...

01/19/2023

The Impact of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function in Adults with Attention-Deficit/Hyperactivity Disorder

Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years). Viloxazine ER effects on executive function (EF) deficits were evalua...

01/19/2023

Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults. The efficacy of viloxazine ER was evaluated in 4 ...

01/19/2023

Efficacy of long-term treatment with daridorexant in patients with insomnia disorder on sleep and daytime functioning: a post-hoc analysis

Abstract: Daridorexant improved night and daytime symptoms of insomnia disorder in two parallel, phase 3, 12-week studies with maintained improvements over a 40-week extension study. The ...

01/19/2023

A Scintigraphy and Pharmacokinetic Study to Evaluate the Absorption and Distribution of Buspirone Hydrochloride from a Triple-Pulse, Timed-Release Tablet.

Abstract: Purpose: To obtain data for development of a precision-timed release buspirone hydrochloride tablet (CTx-2103) that will provide a once-daily, anxiety treatment. This study eluc...

01/19/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder: A Phase 4, Open-Label, Interventional Study

Abstract: Background: Patient life engagement is a broad term describing positive health aspects across four domains (emotional, physical, social, cognitive). The 10-item Inventory of Dep...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products